Ref: CTO 2016 034 [G]

Invertebrates: Encarsia formosa (parasitic wasp) as a biocontrol agent

CTO direction to biosecurity inspectors for the clearance of *Encarsia formosa* (parasitic wasp) from Australia to be used as a biocontrol agent

Pursuant to section 27(1)(d)(iii) of the Biosecurity Act 1993 I, Vicki Melville, Manager Animal Imports, Ministry for Primary Industries (under delegated authority), give the following directions *Encarsia formosa* (parasitic wasp) from Australia to be given clearance in accordance with the following measures, different from those in the applicable import health standard for the importation of invertebrates into New Zealand (INVNONIC.ALL):

Clauses 11.1 and 11.2

Clauses 11.1 and 11.2 of INVNONIC.ALL state:

- 11.1 Following biosecurity authorisation being given, the container must proceed to the approved registered transitional facility which must be operated according to the MAF Standard 154.02.08: Transitional and containment facility for invertebrates.
- On arrival in the transitional facility the culture must be subjected to such disease testing, identity confirmation, treatments or procedures as required by the permit to import, the MAF Standard 154.02.08 and the Animal Imports/Exports Group Manager.

Encarsia formosa (parasitic wasp) from Australia, imported as a biocontrol agent, do not need to be imported into a transitional facility approved to, and operating under, 154.02.08 (Transitional and Containment Facilities for Invertebrates) if the following requirements are met:

- The importation of the product is accompanied by a validated import permit; and
- The importation of the product is accompanied by a veterinary certificate signed by a laboratory audited and approved by the Australian Competent Authority that verifies the following:
 - a) E. formosa are laboratory raised; and
 - b) E. formosa are clear of diseases and parasitoides; and
 - c) the species being sent to New Zealand have been identified as *E. formosa* and not another species.

The reason for directing clearance is that the biosecurity risks associated with this CTO direction have been assessed and are managed effectively. Advice was received from the Science and Risk Assessment Directorate.

This direction takes effect from the date of signing and continues in effect until amended or revoked.